The aim of this paper was to assess the prebiotic properties of lactobionic acid in the human gastrointestinal model. Five different strains of probiotic, or potentially probiotic, bacteria were used in the microencapsulation process; these were Lactobacillus casei Shirota, Lactococcus lactis ATCC1, Lactobacillus fermentum, Bifidobacterium bifidum DSM 20456, and Bifidobacterium bifidum DSM 20082. Starch with a concentration of 4% (w/v) and a degree of substitution of 0.03 was used to produce the microcapsules. The alginian microcapsules we produced functioned as a protective barrier for the probiotic microorganisms closed in them, protecting them from adverse conditions in the human digestive tract. The microorganisms could thus survive the encapsulation process and the in vitro model digestion process while retaining the ability to produce biomass. Factors such as pH and time affect the solution of alginate microcapsules. The capsule solution began when a pH of 7.4 was reached; this corresponded to pH in the target probiotic site, an in vitro model of the colon. The capsules had completely dissolved after 24 h of digestion at a pH of 8. The addition of lactobionic acid stimulated the growth of probiotic and potentially probiotic bacteria, thus confirming its prebiotic properties.

本文的目的是评估乳糖酸在人体胃肠道模型中的益生元特性。在微囊化过程中使用了五种不同的益生菌菌株，或潜在的益生菌菌株；这些是干酪乳杆菌Shirota、乳酸乳球菌ATCC1、发酵乳杆菌、双歧杆菌DSM 20456 和双歧杆菌DSM 20082. 使用浓度为 4% (w/v) 且取代度为 0.03 的淀粉来生产微胶囊。我们生产的海藻胶微胶囊对封闭在其中的益生菌微生物起到保护屏障的作用，保护它们免受人体消化道不利条件的影响。因此，微生物可以在封装过程和体外模型消化过程中存活下来，同时保留产生生物质的能力。pH和时间等因素会影响藻酸盐微胶囊的溶液。当 pH 值达到 7.4 时开始胶囊溶液；这对应于目标益生菌部位的 pH 值，即结肠的体外模型。在 pH 值为 8 下消化 24 小时后，胶囊完全溶解。